Kaj Blennow

Evidence that the gene encoding insulin degrading enzyme influences human lifespan.

Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss?

Synaptic retrogenesis and amyloid-beta in Alzheimer's disease.

A survey of ABCA1 sequence variation confirms association with dementia.

CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.

Sustained release of neuron-specific enolase to serum in amateur boxers.

Sequence variation in SORL1 and dementia risk in Swedes.

Amyloid beta and APP as biomarkers for Alzheimer's disease.

Biological markers of amyloid beta-related mechanisms in Alzheimer's disease.

Total and phosphorylated tau protein as biological markers of Alzheimer's disease.

Subcortical vascular dementia biomarker pattern in mild cognitive impairment.

CSF biomarkers: pinpointing Alzheimer pathogenesis.

Kinesin light chain 1 gene haplotypes in three conformational diseases.

Converging molecular pathways in human neural development and degeneration.

Nrf2-encoding NFE2L2 haplotypes influence disease progression but not risk in Alzheimer's disease and age-related cataract.

Is there a CSF biomarker profile related to depression in elderly women?

Distinct cerebrospinal fluid amyloid beta peptide signatures in sporadic and PSEN1 A431E-associated familial Alzheimer's disease.

Analysis of lipid pathway genes indicates association of sequence variation near SREBF1/TOM1L2/ATPAF2 with dementia risk.

Association of Nrf2-encoding NFE2L2 haplotypes with Parkinson's disease.

Biochemical markers in Alzheimer's disease clinical trials.

Is it time for biomarker-based diagnostic criteria for prodromal Alzheimer's disease?

Acute effect on the Aβ isoform pattern in CSF in response to γ-secretase modulator and inhibitor treatment in dogs.

Effects of cerebrovascular disease on amyloid precursor protein metabolites in cerebrospinal fluid.

Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people.

Lessons from Multicenter Studies on CSF Biomarkers for Alzheimer's Disease.

Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid.

Pleiotropy in the presence of allelic heterogeneity: alternative genetic models for the influence of APOE on serum LDL, CSF amyloid-β42, and dementia.

Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease.

Biomarkers in Alzheimer's disease drug development.

Use of theragnostic markers to select drugs for phase II/III trials for Alzheimer disease.

Impaired lipoprotein receptor-mediated peripheral binding of plasma amyloid-β is an early biomarker for mild cognitive impairment preceding Alzheimer's disease.

Genetic association of sequence variants near AGER/NOTCH4 and dementia.

Cerebrospinal fluid analysis should be considered in patients with cognitive problems.

Biomarker-based dissection of neurodegenerative diseases.

Identification of novel α-synuclein isoforms in human brain tissue by using an online nanoLC-ESI-FTICR-MS method.

Cerebrospinal fluid matrix metalloproteinases and tissue inhibitor of metalloproteinases in combination with subcortical and cortical biomarkers in vascular dementia and Alzheimer's disease.

Biomarkers for microglial activation in Alzheimer's disease.

CSF-biomarkers in Olympic boxing: diagnosis and effects of repetitive head trauma.

An online nano-LC-ESI-FTICR-MS method for comprehensive characterization of endogenous fragments from amyloid β and amyloid precursor protein in human and cat cerebrospinal fluid.

CSF T-Tau/Aβ42 predicts white matter microstructure in healthy adults at risk for Alzheimer's disease.

Cerebrospinal fluid biomarkers for Alzheimer's disease: more to come?

Peptidome analysis of cerebrospinal fluid by LC-MALDI MS.

Proficiency testing programs for Alzheimer's disease cerebrospinal fluid biomarkers.

Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid β42.

Low cerebrospinal fluid sulfatide predicts progression of white matter lesions: The LADIS study.

Fluid biomarkers in Alzheimer disease.

Serum levels of LIGHT in MS.

The neuropathology and neurobiology of traumatic brain injury.

Dose and plasma concentration of galantamine in Alzheimer's disease - clinical application.

Soluble amyloid precursor protein α and β in CSF in Alzheimer's disease.

Acute and chronic traumatic encephalopathies: pathogenesis and biomarkers.

The application of cerebrospinal fluid biomarkers in early diagnosis of Alzheimer disease.

Evaluating amyloid-β oligomers in cerebrospinal fluid as a biomarker for Alzheimer's disease.

Cerebrospinal fluid biomarkers in cardiac arrest survivors.

CSF Presenilin-1 complexes are increased in Alzheimer's disease.

Increased CSF levels of phosphorylated neurofilament heavy protein following bout in amateur boxers.

Automated cerebrospinal fluid cell count--new reference ranges and evaluation of its clinical use in central nervous system infections.

[Exercise and weight loss does not reduce cardiovascular risk in type 2 diabetes].

The cerebrospinal fluid "Alzheimer profile": easily said, but what does it mean?

CSF Aβ42 predicts early-onset dementia in Parkinson disease.

Taking stock: A multistakeholder perspective on improving the delivery of care and the development of treatments for Alzheimer's disease.

Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease.

Mass spectrometry-based candidate reference measurement procedure for quantification of amyloid-β in cerebrospinal fluid.

Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.

Higher CSF interleukin-6 and CSF interleukin-8 in current depression in older women. Results from a population-based sample.

Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's disease.

Tau, s-100 calcium-binding protein B, and neuron-specific enolase as biomarkers of concussion-reply.

Agitation in dementia: relation to core cerebrospinal fluid biomarker levels.

Genetic variants of GSK3B are associated with biomarkers for Alzheimer's disease and cognitive function.

Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases.

Rarity of the Alzheimer disease-protective APP A673T variant in the United States.

Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease.

CSF biomarkers for the differential diagnosis of Alzheimer's disease: A large-scale international multicenter study.

Amyloid biomarkers in Alzheimer's disease.

Serum visinin-like protein-1 in concussed professional ice hockey players.

Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis.

Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects.

Cerebrospinal Fluid Patterns and the Risk of Future Dementia in Early, Incident Parkinson Disease.

Case Report of Complex Amyotrophic Lateral Sclerosis with Cognitive Impairment and Cortical Amyloid Deposition.

Does Caffeine Consumption Modify Cerebrospinal Fluid Amyloid-β Levels in Patients with Alzheimer's Disease?

Increased Cerebrospinal Fluid Level of Insulin-like Growth Factor-II in Male Patients with Alzheimer's Disease.

Dissecting IWG-2 typical and atypical Alzheimer's disease: insights from cerebrospinal fluid analysis.

Greater specificity for cerebrospinal fluid P-tau231 over P-tau181 in the differentiation of healthy controls from Alzheimer's disease.

Cerebrospinal fluid substance P concentrations are elevated in patients with Alzheimer's disease.

The past and the future of Alzheimer's disease CSF biomarkers-a journey toward validated biochemical tests covering the whole spectrum of molecular events.

The Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative Diseases.

Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of β-amyloid (1-42) in human cerebrospinal fluid.

Cerebrospinal Fluid Biomarker for Alzheimer Disease Predicts Postoperative Cognitive Dysfunction.

Cerebrospinal fluid markers of central nervous system injury in decompression illness - a case-controlled pilot study.

APLP1 as a cerebrospinal fluid biomarker for γ-secretase modulator treatment.

Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer's disease.

Serum Neurofilament Light in American Football Athletes over the Course of a Season.

HNK-1 Carrier Glycoproteins Are Decreased in the Alzheimer's Disease Brain.

Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease.

Effect of Docosahexaenoic Acid on a Biomarker of Head Trauma in American Football.

Cerebral white matter lesions - associations with Aβ isoforms and amyloid PET.

YKL-40 is a CSF biomarker of intrathecal inflammation in secondary progressive multiple sclerosis.

Increased amyloidogenic APP processing in APOE ɛ4-negative individuals with cerebral β-amyloidosis.

A single dose of the γ-secretase inhibitor semagacestat alters the cerebrospinal fluid peptidome in humans.

Cerebrospinal fluid levels of insulin, leptin, and agouti-related protein in relation to BMI in pregnant women.

Cerebrospinal fluid biomarkers in Alzheimer's and Parkinson's diseases-From pathophysiology to clinical practice.

CSF Aβ1-42 - an excellent but complicated Alzheimer's biomarker - a route to standardisation.

Low Circulating Acute Brain-Derived Neurotrophic Factor Levels Are Associated With Poor Long-Term Functional Outcome After Ischemic Stroke.

Blood biomarkers indicate mild neuroaxonal injury and increased amyloid β production after transient hypoxia during breath-hold diving.

Cerebrospinal fluid interferon alpha levels correlate with neurocognitive impairment in ambulatory HIV-Infected individuals.

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease.

Reference measurement procedure for CSF amyloid beta (Aβ)1-42 and the CSF Aβ1-42 /Aβ1-40 ratio - a cross-validation study against amyloid PET.

Specific Triazine Herbicides Induce Amyloid-β42 Production.

Associations between Performance on an Abbreviated CogState Battery, Other Measures of Cognitive Function, and Biomarkers in People at Risk for Alzheimer's Disease.

CSF profiling of the human brain enriched proteome reveals associations of neuromodulin and neurogranin to Alzheimer's disease.

No diurnal variation of classical and candidate biomarkers of Alzheimer's disease in CSF.

Cerebrospinal Fluid Amyloid Beta and Tau Concentrations Are Not Modulated by 16 Weeks of Moderate- to High-Intensity Physical Exercise in Patients with Alzheimer Disease.

Neurochemical Aftermath of Repetitive Mild Traumatic Brain Injury.

Preclinical Amyloid-β and Axonal Degeneration Pathology in Delirium.

Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team.

Plasma tau in Alzheimer disease.

Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis.

Cerebrospinal Fluid Aβ42/40 Corresponds Better than Aβ42 to Amyloid PET in Alzheimer's Disease.

CSF neurofilament light levels predict hippocampal atrophy in cognitively healthy older adults.

Serum neurofilament light protein predicts clinical outcome in traumatic brain injury.

Association of Amyloid Pathology With Myelin Alteration in Preclinical Alzheimer Disease.

Traumatic brain injuries.

Feasibility of Lumbar Puncture in the Study of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in Subjects with Down Syndrome.

The Effects of Gene Mutations on Default Mode Network in Familial Alzheimer's Disease.

Neurofilaments in blood and CSF for diagnosis and prediction of onset in Creutzfeldt-Jakob disease.

Genome-wide, high-content siRNA screening identifies the Alzheimer's genetic risk factor FERMT2 as a major modulator of APP metabolism.

Delineating Amyloid Plaque Associated Neuronal Sphingolipids in Transgenic Alzheimer's Disease Mice (tgArcSwe) Using MALDI Imaging Mass Spectrometry.

Cerebrospinal fluid microglia and neurodegenerative markers in twins concordant and discordant for psychotic disorders.

Expanding the cerebrospinal fluid endopeptidome.

Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes.

Effect of Spinal Manometers on Cerebrospinal Fluid Amyloid-β Concentration.

Increased blood-brain barrier permeability is associated with dementia and diabetes but not amyloid pathology or APOE genotype.

Plasma concentrations of free amyloid β cannot predict the development of Alzheimer's disease.

Genome-wide association study identifies MAPT locus influencing human plasma tau levels.

Neurofilament Protein and Antineurofilament Antibodies Following Traumatic Brain Injury-Reply.

Accuracy of cerebrospinal fluid Aβ1-42 measurements: evaluation of pre-analytical factors using a novel Elecsys immunosassay.

Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder.

The effects of different familial Alzheimer's disease mutations on APP processing in vivo.

Predicting progression to dementia in persons with mild cognitive impairment using cerebrospinal fluid markers.

Ex vivo (18)O-labeling mass spectrometry identifies a peripheral amyloid β clearance pathway.

Author response: Calcium supplementation and risk of dementia in women with cerebrovascular disease.

Tau or neurofilament light-Which is the more suitable biomarker for Huntington's disease?

Genome-wide association study identifies four novel loci associated with Alzheimer's endophenotypes and disease modifiers.

The immune response of the human brain to abdominal surgery.

Two-level diagnostic classification using cerebrospinal fluid YKL-40 in Alzheimer's disease.

Effects of Risperidone and Galantamine Treatment on Alzheimer's Disease Biomarker Levels in Cerebrospinal Fluid.

Astroglial activation and altered amyloid metabolism in human repetitive concussion.

Phenotypic Screening Identifies Modulators of Amyloid Precursor Protein Processing in Human Stem Cell Models of Alzheimer's Disease.

Microstructural white matter alterations in preclinical Alzheimer's disease detected using free water elimination diffusion tensor imaging.

Clinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework.

Serum neurofilament light as a biomarker for mild traumatic brain injury in contact sports.

Inflammation, Amyloid, and Atrophy in The Aging Brain: Relationships with Longitudinal Changes in Cognition.

A Season of American Football Is Not Associated with Changes in Plasma Tau.

Increased levels of ascorbic acid in the cerebrospinal fluid of cognitively intact elderly patients with major depression: a preliminary study.

Neuroinflammation and Tau Interact with Amyloid in Predicting Sleep Problems in Aging Independently of Atrophy.

Cerebrospinal fluid monoamine metabolite profiles in bipolar disorder, ADHD, and controls.

Reduced Cerebrospinal Fluid Concentration of Apolipoprotein A-I in Patients with Alzheimer's Disease.

Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers.

A Review of Fluid Biomarkers for Alzheimer's Disease: Moving from CSF to Blood.

Intracranial Arterial 4D Flow in Individuals with Mild Cognitive Impairment is Associated with Cognitive Performance and Amyloid Positivity.

Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders.

Serum tau and neurological outcome in cardiac arrest.

A Parallel Reaction Monitoring Mass Spectrometric Method for Analysis of Potential CSF Biomarkers for Alzheimer's Disease.

Neurofilament light protein in CSF and blood is associated with neurodegeneration and disease severity in Huntington's disease R6/2 mice.

24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet): a randomised, double-blind, controlled trial.

Low-dose γ-secretase inhibition increases secretion of Aβ peptides and intracellular oligomeric Aβ.

Obstructive Sleep Apnea Severity Affects Amyloid Burden in Cognitively Normal Elderly: A Longitudinal Study.

Central and Peripheral Leptin and Agouti-Related Protein during and after Pregnancy in Relation to Weight Change.